A Randomized Multicenter Phase II Trial of Patupilone (EPO906) plus Prednisone versus Docetaxel (Taxotere) plus Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer

Mise à jour : Il y a 5 ans
Référence : EUCTR2006-001822-23

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To determine the antitumor response of patupilone administered I.V. at 10 mg/m2 once every three weeks and docetaxel administered at 75 mg/m2 once every three weeks as defined by the effect of treatment on PSA concentration. The PSA decrease will be documented in accordance with the consensus guidelines of the PSA working group.


Critère d'inclusion

  • Cancer of the prostate is the most commonly diagnosed neoplasm in men in the United States after skin cancer. In 2002, over 189,000 new cases were diagnosed in United States representing 30% of all new cancer diagnoses in men comparable to the incidence of breast cancer in women. Patients with metastatic androgen-independent prostate cancer have a progressive and morbid disease with a median survival of 10 to 12 months